$NMRD
Nemaura Medical Inc. Stock $nmrd

$nmrd Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-Q Financial Statement

#000155335023000139 Filed on February 24, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2021 Q4
Revenue	$0.00	$3.017K	$183.6K
YoY Change	-100.0%	-98.36%
Cost Of Revenue	$0.00	$2.971K	$172.4K
YoY Change	-100.0%	-98.28%
Gross Profit	$0.00	$46.00	$11.24K
YoY Change	-100.0%	-99.59%
Gross Profit Margin		1.52%	6.12%
Selling, General & Admin	$1.271M	$239.6K	$1.391M
YoY Change	-37.14%	-82.78%	139.88%
% of Gross Profit		520934.78%	12377.94%
Research & Development	$557.8K	$393.7K	$412.3K
YoY Change	-2.03%	-4.51%	-15.85%
% of Gross Profit		855971.74%	3668.51%
Depreciation & Amortization	$175.6K	$95.92K	$58.06K
YoY Change	94.96%	65.21%	93.53%
% of Gross Profit		208521.74%	516.55%
Operating Expenses	$1.829M	$633.4K	$1.804M
YoY Change	-29.42%	-64.88%	68.56%
Operating Profit	-$1.829M	-$633.3K	-$1.792M
YoY Change	-25.14%	-64.67%	67.51%
Interest Expense	-$396.1K	-$1.083M	-$1.639M
YoY Change	-74.03%	-33.93%	331.36%
% of Operating Profit
Other Income/Expense, Net	$1.864M	$273.00	$4.382K
YoY Change		-93.77%
Pretax Income	-$4.683M	-$1.716M	-$3.432M
YoY Change	18.03%	-49.99%	136.66%
Income Tax
% Of Pretax Income
Net Earnings	-$4.683M	-$1.716M	-$3.432M
YoY Change	29.46%	-49.99%	136.66%
Net Earnings / Revenue		-56886.91%	-1868.74%
Basic Earnings Per Share		-$0.07
Diluted Earnings Per Share	-$0.17	-$0.07	-$147.2K
COMMON SHARES
Basic Shares Outstanding	28.90M shares	24.10M shares	23.31M shares
Diluted Shares Outstanding		24.10M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$10.11M	$7.341M	$23.05M
YoY Change	-43.07%	-68.15%	54.05%
Cash & Equivalents	$10.11M	$7.341M	$23.05M
Short-Term Investments
Other Short-Term Assets	$1.268M	$1.217M	$472.4K
YoY Change	68.98%	157.69%	-44.43%
Inventory	$1.755M	$2.352M	$1.384M
Prepaid Expenses
Receivables	$0.00	$25.32K	$152.6K
Other Receivables	$409.7K	$0.00	$0.00
Total Short-Term Assets	$13.54M	$10.94M	$25.06M
YoY Change	-32.61%	-56.35%	50.66%
LONG-TERM ASSETS
Property, Plant & Equipment	$641.9K	$581.9K	$454.3K
YoY Change	20.54%	28.1%	127.14%
Goodwill
YoY Change
Intangibles	$384.1K
YoY Change	-74.07%
Long-Term Investments
YoY Change
Other Assets		$2.026M
YoY Change
Total Long-Term Assets	$1.026M	$2.026M	$2.018M
YoY Change	-49.04%	0.37%	99.84%
TOTAL ASSETS
Total Short-Term Assets	$13.54M	$10.94M	$25.06M
Total Long-Term Assets	$1.026M	$2.026M	$2.018M
Total Assets	$14.56M	$12.96M	$27.07M
YoY Change	-34.11%	-52.12%	53.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$326.6K	$171.2K	$176.6K
YoY Change	139.63%	-3.06%	3.89%
Accrued Expenses	$130.7K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$16.94M	$11.51M	$14.85M
YoY Change	-11.71%	-22.48%	311.38%
Total Short-Term Liabilities	$22.27M	$13.22M	$16.14M
YoY Change	8.19%	-18.07%	270.93%
LONG-TERM LIABILITIES
Long-Term Debt	$3.088M	$8.558M	$8.713M
YoY Change		-1.78%	412.53%
Other Long-Term Liabilities	$1.022M	$1.043M	$1.202M
YoY Change	-2.96%	-13.23%	-4.63%
Total Long-Term Liabilities	$4.109M	$9.600M	$9.915M
YoY Change	290.28%	-3.17%	234.96%
TOTAL LIABILITIES
Total Short-Term Liabilities	$22.27M	$13.22M	$16.14M
Total Long-Term Liabilities	$4.109M	$9.600M	$9.915M
Total Liabilities	$26.38M	$22.82M	$26.05M
YoY Change	21.92%	-12.4%	256.36%
SHAREHOLDERS EQUITY
Retained Earnings	-$51.88M	-$47.19M
YoY Change	37.49%
Common Stock	$41.02M	$38.32M
YoY Change	7.05%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$11.81M	-$9.859M	$1.024M
YoY Change
Total Liabilities & Shareholders Equity	$14.56M	$12.96M	$27.07M
YoY Change	-34.11%	-52.12%	53.48%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2021 Q4
OPERATING ACTIVITIES
Net Income	-$4.683M	-$1.716M	-$3.432M
YoY Change	29.46%	-49.99%	136.66%
Depreciation, Depletion And Amortization	$175.6K	$95.92K	$58.06K
YoY Change	94.96%	65.21%	93.53%
Cash From Operating Activities	-$2.362M	-$1.541M	-$877.4K
YoY Change	9.81%	75.64%	-46.17%
INVESTING ACTIVITIES
Capital Expenditures	$100.4K	$57.64K	-$193.7K
YoY Change	-231.31%	-129.75%	-63.44%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$100.4K	-$57.64K	-$193.7K
YoY Change	31.31%	-70.25%	-63.44%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$118.8K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	5.356M	-1.700M	-2.586M
YoY Change	-281.78%	-34.27%	761.86%
NET CHANGE
Cash From Operating Activities	-2.362M	-1.541M	-877.4K
Cash From Investing Activities	-100.4K	-57.64K	-193.7K
Cash From Financing Activities	5.356M	-1.700M	-2.586M
Net Change In Cash	2.894M	-3.298M	-3.657M
YoY Change	-155.94%	-9.8%	48.65%
FREE CASH FLOW
Cash From Operating Activities	-$2.362M	-$1.541M	-$877.4K
Capital Expenditures	$100.4K	$57.64K	-$193.7K
Free Cash Flow	-$2.462M	-$1.599M	-$683.7K
YoY Change	18.7%	133.85%	-37.85%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Local Phone Number LocalPhoneNumber	416-8000
	dei	Entity Central Index Key EntityCentralIndexKey	0001602078
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38355
	dei	Entity Registrant Name EntityRegistrantName	Nemaura Medical Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-5027260
	dei	Entity Address Address Line1 EntityAddressAddressLine1	57 West 57th Street
	dei	Entity Address City Or Town EntityAddressCityOrTown	Manhattan
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10019
	dei	City Area Code CityAreaCode	646
	dei	Security12b Title Security12bTitle	Common Stock
	dei	Trading Symbol TradingSymbol	NMRD
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	28899402	shares
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7340840	usd
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17749233	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	1217237	usd
CY2022Q1	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	750167	usd
CY2022Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	25320	usd
CY2022Q1	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	101297	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	2352407	usd
CY2022Q1	us-gaap	Inventory Net InventoryNet	1487771	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	10935804	usd
CY2022Q1	us-gaap	Assets Current AssetsCurrent	20088468	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	581903	usd
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	532508	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1443991	usd
CY2022Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1480980	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2025894	usd
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2013488	usd
CY2022Q4	us-gaap	Assets Assets	12961698	usd
CY2022Q1	us-gaap	Assets Assets	22101956	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	171207	usd
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	136310	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	390858	usd
CY2022Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	558426	usd
CY2022Q4	nmrd	Foreign Currency Contract ForeignCurrencyContract	1075692	usd
CY2022Q1	nmrd	Foreign Currency Contract ForeignCurrencyContract	440196	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	11512711	usd
CY2022Q1	us-gaap	Notes Payable Current NotesPayableCurrent	19188724	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	69681	usd
CY2022Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	259256	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13220149	usd
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	20582912	usd
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	8557548	usd
CY2022Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	0	usd
CY2022Q4	us-gaap	Deferred Revenue And Credits Noncurrent DeferredRevenueAndCreditsNoncurrent	1042710	usd
CY2022Q1	us-gaap	Deferred Revenue And Credits Noncurrent DeferredRevenueAndCreditsNoncurrent	1052960	usd
CY2022Q4	us-gaap	Liabilities Liabilities	22820407	usd
CY2022Q1	us-gaap	Liabilities Liabilities	21635872	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	42000000	shares
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	42000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24103196	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24103196	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24102866	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24102866	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	24103	usd
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	24103	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	38296198	usd
CY2022Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	38295775	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-47192364	usd
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-37731476	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-986646	usd
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-122318	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-9858709	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	466084	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12961698	usd
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	22101956	usd
CY2022Q4	us-gaap	Revenues Revenues	3017	usd
CY2021Q4	us-gaap	Revenues Revenues	183628	usd
	us-gaap	Revenues Revenues	77044	usd
	us-gaap	Revenues Revenues	183628	usd
CY2022Q4	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2971	usd
CY2021Q4	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	172393	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	75327	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	172393	usd
CY2022Q4	us-gaap	Gross Profit GrossProfit	46	usd
CY2021Q4	us-gaap	Gross Profit GrossProfit	11235	usd
	us-gaap	Gross Profit GrossProfit	1717	usd
	us-gaap	Gross Profit GrossProfit	11235	usd
CY2022Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	393747	usd
CY2021Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	412341	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	980862	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	987711	usd
CY2022Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	239628	usd
CY2021Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1391278	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4329306	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4151380	usd
CY2022Q4	us-gaap	Operating Expenses OperatingExpenses	633375	usd
CY2021Q4	us-gaap	Operating Expenses OperatingExpenses	1803619	usd
	us-gaap	Operating Expenses OperatingExpenses	5310168	usd
	us-gaap	Operating Expenses OperatingExpenses	5139091	usd
	nmrd	Exercise Of Warrants Amount ExerciseOfWarrantsAmount	2963658	usd
CY2022Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-633329	usd
CY2021Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-1792384	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-5308451	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-5127856	usd
CY2022Q4	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1082949	usd
CY2021Q4	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1639184	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-4152437	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-5141701	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-1716278	usd
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-3431568	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9460888	usd
	us-gaap	Net Income Loss NetIncomeLoss	-10269557	usd
CY2022Q4	us-gaap	Translation Adjustment Functional To Reporting Currency Increase Decrease Gross Of Tax TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax	556080	usd
CY2021Q4	us-gaap	Translation Adjustment Functional To Reporting Currency Increase Decrease Gross Of Tax TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax	-25065	usd
	us-gaap	Translation Adjustment Functional To Reporting Currency Increase Decrease Gross Of Tax TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax	-864328	usd
	us-gaap	Translation Adjustment Functional To Reporting Currency Increase Decrease Gross Of Tax TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax	-142922	usd
CY2022Q4	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1160198	usd
CY2021Q4	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3456633	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10325216	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10412479	usd
CY2022Q4	nmrd	Net Loss Per Share Basic And Diluted NetLossPerShareBasicAndDiluted	-0.07
CY2021Q4	nmrd	Net Loss Per Share Basic And Diluted NetLossPerShareBasicAndDiluted	-0.15
	nmrd	Net Loss Per Share Basic And Diluted NetLossPerShareBasicAndDiluted	-0.39
	nmrd	Net Loss Per Share Basic And Diluted NetLossPerShareBasicAndDiluted	-0.44
CY2022Q4	nmrd	Weighted Average Number Of Shares Outstanding WeightedAverageNumberOfSharesOutstanding	24103196	shares
CY2021Q4	nmrd	Weighted Average Number Of Shares Outstanding WeightedAverageNumberOfSharesOutstanding	23313629	shares
	nmrd	Weighted Average Number Of Shares Outstanding WeightedAverageNumberOfSharesOutstanding	24102976	shares
	nmrd	Weighted Average Number Of Shares Outstanding WeightedAverageNumberOfSharesOutstanding	23244345	shares
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-8698934	usd
CY2022Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	423	usd
CY2022Q4	us-gaap	Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax	556080	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-1716278	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-9858709	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	4365984	usd
CY2021Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	114409	usd
CY2021Q4	us-gaap	Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax	-25065	usd
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-3431568	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	1023760	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	466084	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	423	usd
	us-gaap	Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax	-864328	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9460888	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-9858709	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	8358172	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	114409	usd
	us-gaap	Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax	-142922	usd
	us-gaap	Net Income Loss NetIncomeLoss	-10269557	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17749233	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	1023760	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9460888	usd
	us-gaap	Net Income Loss NetIncomeLoss	-10269557	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	268595	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	139751	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	4152437	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	5141701	usd
	nmrd	Change In Fair Value Of Foreign Currency Contract ChangeInFairValueOfForeignCurrencyContract	635494	usd
	nmrd	Change In Fair Value Of Foreign Currency Contract ChangeInFairValueOfForeignCurrencyContract	199522	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	467070	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-797155	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	864636	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	533656	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	34897	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-77075	usd
	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	-75977	usd
	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	301387	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-167568	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	264786	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-297419	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	285266	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6090181	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4353494	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	135168	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	60241	usd
	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	27879	usd
	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	460466	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	275758	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	359301	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-438805	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-880008	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	696	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	118791	usd
	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	273	usd
	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	4382	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	4700000	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2963658	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	7974282	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	6500000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-3273859	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-3421933	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-605548	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-163658	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-10408393	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-8819093	usd
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	31865371	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7340840	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23046278	usd
	nmrd	Release Of Prepayment From Equity Compensation ReleaseOfPrepaymentFromEquityCompensation	0	usd
	nmrd	Release Of Prepayment From Equity Compensation ReleaseOfPrepaymentFromEquityCompensation	50000	usd
	nmrd	Monitoring Fees Related To Notes Payable MonitoringFeesRelatedToNotesPayable	1522372	usd
	nmrd	Monitoring Fees Related To Notes Payable MonitoringFeesRelatedToNotesPayable	0	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-47192364	usd
CY2022Q4	us-gaap	Cash Cash	7340840	usd
CY2022Q1	nmrd	Foreign Currency Contract ForeignCurrencyContract	440196	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84B_eus-gaap--UseOfEstimates_zbb69vHc3Phk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span style="text-decoration: underline"><span id="xdx_868_zweO9JCT16w8">Use of Estimates</span></span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ materially from those estimates. The Company’s most significant estimates include the useful life of intangible assets, valuation of foreign currency contract and valuation allowance on deferred tax assets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our estimates are often based on complex judgments, probabilities and assumptions that management believes to be reasonable, but that are inherently uncertain and unpredictable. It is also possible that other professionals, applying reasonable judgment to the same facts and circumstances, could develop and support a range of alternative estimated amounts. For a complete discussion of our critical accounting policies, see the “Critical Accounting Policies” section of the Management’s Discussion & Analysis in our March 31, 2022 Form 10-K. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2022Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2022Q1	us-gaap	Advance Royalties AdvanceRoyalties	1310000	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	70000	usd
CY2022Q1	us-gaap	Deferred Revenue DeferredRevenue	259000	usd
	us-gaap	Finite Lived Intangible Assets Remaining Amortization Period1 FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1	P20Y
CY2014Q1	us-gaap	Advance Royalties AdvanceRoyalties	1000000	gbp
CY2022Q4	us-gaap	Advance Royalties AdvanceRoyalties	1200000	usd
	nmrd	Related Party Transaction Due From To Related Partie RelatedPartyTransactionDueFromToRelatedPartie	-101297	usd
	nmrd	Related Party Transaction Due From To Related Partie RelatedPartyTransactionDueFromToRelatedPartie	148795	usd
CY2022	nmrd	Related Party Transaction Due From To Related Partie RelatedPartyTransactionDueFromToRelatedPartie	148795	usd
	nmrd	Amounts Invoiced By Pharma To Ddl AmountsInvoicedByPharmaToDdl	2833546	usd
	nmrd	Amounts Invoiced By Pharma To Ddl AmountsInvoicedByPharmaToDdl	2114801	usd
CY2022	nmrd	Amounts Invoiced By Pharma To Ddl AmountsInvoicedByPharmaToDdl	3245985	usd
	nmrd	Amounts Invoiced By Ddl To Pharma AmountsInvoicedByDdlToPharma	-3159	usd
	nmrd	Amounts Invoiced By Ddl To Pharma AmountsInvoicedByDdlToPharma	-2495	usd
CY2022	nmrd	Amounts Invoiced By Ddl To Pharma AmountsInvoicedByDdlToPharma	-2495	usd
	nmrd	Amounts Repaid By Ddl To Pharma AmountsRepaidByDdlToPharma	-2785487	usd
	nmrd	Amounts Repaid By Ddl To Pharma AmountsRepaidByDdlToPharma	-2316544	usd
CY2022	nmrd	Amounts Repaid By Ddl To Pharma AmountsRepaidByDdlToPharma	-3492962	usd
	nmrd	Foreign Currency Translation Related Party ForeignCurrencyTranslationRelatedParty	31077	usd
	nmrd	Foreign Currency Translation Related Party ForeignCurrencyTranslationRelatedParty	-97149	usd
CY2022	nmrd	Foreign Currency Translation Related Party ForeignCurrencyTranslationRelatedParty	-620	usd
	nmrd	Related Party Transaction Due From To Related Parties RelatedPartyTransactionDueFromToRelatedParties	-25320	usd
	nmrd	Related Party Transaction Due From To Related Parties RelatedPartyTransactionDueFromToRelatedParties	-152592	usd
CY2022	nmrd	Related Party Transaction Due From To Related Parties RelatedPartyTransactionDueFromToRelatedParties	-101297	usd
CY2021Q1	us-gaap	Payments For Advance To Affiliate PaymentsForAdvanceToAffiliate	15000	usd
CY2022Q2	us-gaap	Redemption Premium RedemptionPremium	2000000	usd
CY2022Q4	us-gaap	Capital Leases Future Minimum Payments Receivable In Two Years CapitalLeasesFutureMinimumPaymentsReceivableInTwoYears	11512711	usd
CY2022Q4	us-gaap	Capital Leases Future Minimum Payments Receivable In Three Years CapitalLeasesFutureMinimumPaymentsReceivableInThreeYears	8557548	usd
CY2022Q4	us-gaap	Capital Leases Future Minimum Payments Receivable Due Thereafter CapitalLeasesFutureMinimumPaymentsReceivableDueThereafter	20070259	usd
CY2022Q4	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	696	usd
CY2022Q4	us-gaap	Other Expenses OtherExpenses	273	usd
	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	0	shares
	nmrd	Warrants Exercised WarrantsExercised	366892	shares
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	2963658	usd
CY2021Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1573098	usd
CY2021Q4	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	22524	shares
CY2021Q4	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	118791	usd
CY2021Q4	us-gaap	Other Expenses OtherExpenses	4382	usd
CY2021Q4	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	0	shares
	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	0	shares
CY2022Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1716278	usd
CY2021Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3431568	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9460888	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10269557	usd
CY2022Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24103196	shares
CY2021Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23313629	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24102976	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23244345	shares
CY2022Q4	nmrd	Basic And Diluted Loss Per Share BasicAndDilutedLossPerShare	-0.07
CY2021Q4	nmrd	Basic And Diluted Loss Per Share BasicAndDilutedLossPerShare	-0.15
	nmrd	Basic And Diluted Loss Per Share BasicAndDilutedLossPerShare	-0.39
	nmrd	Basic And Diluted Loss Per Share BasicAndDilutedLossPerShare	-0.44
CY2021Q4	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	1573098	usd
	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	1573098	usd

Files In Submission

Name	View Source	Status
0001553350-23-000139-index-headers.html	Edgar Link	pending
0001553350-23-000139-index.html	Edgar Link	pending
0001553350-23-000139.txt	Edgar Link	pending
0001553350-23-000139-xbrl.zip	Edgar Link	pending
ex31x1.htm	Edgar Link	pending
ex31x2.htm	Edgar Link	pending
ex32x1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nmrd-20221231.xsd	Edgar Link	pending
nmrd_10q.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
nmrd-20221231_cal.xml	Edgar Link	unprocessable
nmrd-20221231_def.xml	Edgar Link	unprocessable
nmrd-20221231_lab.xml	Edgar Link	unprocessable
nmrd-20221231_pre.xml	Edgar Link	unprocessable
nmrd_10q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NMRD
Nemaura Medical Inc. Stock $nmrd

2023 Q1 Form 10-Q Financial Statement

#000155335023000139 Filed on February 24, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NMRD Nemaura Medical Inc. Stock $nmrd

2023 Q1 Form 10-Q Financial Statement

#000155335023000139 Filed on February 24, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NMRD
Nemaura Medical Inc. Stock $nmrd